These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
228 related articles for article (PubMed ID: 31112621)
21. The Role of Suboptimal Concentrations of Nebulized Tobramycin in Driving Antimicrobial Resistance in Moore JE; Millar BC; Ollman-Selinger M; Cambridge L Respir Care; 2021 Sep; 66(9):1446-1457. PubMed ID: 34031222 [TBL] [Abstract][Full Text] [Related]
22. Higher tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis. Coates AL; Denk O; Leung K; Ribeiro N; Chan J; Green M; Martin S; Charron M; Edwardes M; Keller M Pediatr Pulmonol; 2011 Apr; 46(4):401-8. PubMed ID: 21438171 [TBL] [Abstract][Full Text] [Related]
23. [Nebulized colistin versus tobramycin in the treatment of chronic Pseudomonas colonization in cystic fibrosis patients]. Quintana-Gallego E; Lopez-Campos JL; Calero C; Dapena FJ Med Clin (Barc); 2014 Jan; 142(2):59-63. PubMed ID: 23369499 [TBL] [Abstract][Full Text] [Related]
24. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Geller DE; Konstan MW; Smith J; Noonberg SB; Conrad C Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404 [TBL] [Abstract][Full Text] [Related]
25. Serum tobramycin levels following delivery of tobramycin (Tobi) via eFlow advanced nebuliser in children with cystic fibrosis. Guy EL; Bosomworth M; Denton M; Conway SP; Brownlee KG; Lee TW J Cyst Fibros; 2010 Jul; 9(4):292-5. PubMed ID: 20427245 [TBL] [Abstract][Full Text] [Related]
26. Inhaled antibiotic therapy in evidence: what delivery device? Dennis JH; Pieron CA J Cyst Fibros; 2002 Dec; 1(Suppl 2):209-14. PubMed ID: 15463837 [TBL] [Abstract][Full Text] [Related]
27. Accounting for radioactivity before and after nebulization of tobramycin to insure accuracy of quantification of lung deposition. Coates AL; Dinh L; MacNeish CF; Rollin T; Gagnon S; Ho SL; Lands LC J Aerosol Med; 2000; 13(3):169-78. PubMed ID: 11066020 [TBL] [Abstract][Full Text] [Related]
28. Tobramycin inhalation powder in cystic fibrosis patients: response by age group. Geller DE; Nasr SZ; Piggott S; He E; Angyalosi G; Higgins M Respir Care; 2014 Mar; 59(3):388-98. PubMed ID: 23983274 [TBL] [Abstract][Full Text] [Related]
29. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations. Al-Aloul M; Nazareth D; Walshaw M J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814 [TBL] [Abstract][Full Text] [Related]
30. In vitro aerodynamic characterization of the dose emitted during nebulization of tobramycin high strength solution by novel and jet nebulizer delivery systems. Mashat M; Clark BJ; Assi KH; Chrystyn H Pulm Pharmacol Ther; 2016 Apr; 37():37-42. PubMed ID: 26747025 [TBL] [Abstract][Full Text] [Related]
31. Inhalation of tobramycin in cystic fibrosis. Part 2: optimization of the tobramycin solution for a jet and an ultrasonic nebulizer. Le Brun PP; de Boer AH; Gjaltema D; Hagedoorn P; Heijerman HG; Frijlink HW Int J Pharm; 1999 Nov; 189(2):215-25. PubMed ID: 10536250 [TBL] [Abstract][Full Text] [Related]